Zimed set for expansion after £5m management buy-out:
This article was originally published in Clinica
Executive Summary
Welsh medical device company Zimed is targeting expansion in the UK and international healthcare markets after a £5m ($10.2m) management buy-out (MBO). The Denbighshire, North Wales-based firm has acquired the intellectual property and commercial arrangements for the AD syringe driver and Red Eye intravenous monitor from its former parent company Zi Medical. Neither of the products are ready for market yet, but the company has signed an exclusive UK distribution agreement with the clinical technologies and services subsidiary of Cardinal Health. The company also acquired the research and development team associated to the technology. Zimed's management team of Steve Stocks, Raj Uppal and founder George Gallagher led the MBO.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.